fda tirzepatide injection shortage resolved oct 2 2024 Eli Lilly's is off the FDA's drug list: Here's what it means Lilly's weight-loss drug removed from

dose escalation may be delayed by 1 additional week if necessary: Week 1: Inject 0.6 mg subcutaneously once a day Week 2: Inject 1.2 mg subcutaneously once a day Week 3: Inject 1.8 mg subcutaneously once a day Week 4: Inject 2.4 mg subcutaneously once a day Week 5: Inject 3 mg subcutaneously once a day Maintenance dose : 3 mg subcutaneously once a day-If maintenance dose is not tolerated, discontinuation is recommended

No, injecting into the same spot repeatedly increases your risk of lipodystrophya condition where fatty tissue shrinks, hardens, or develops nodules

Talk to a licensed healthcare provider first if you have diabetes or prediabetes, take metformin, take insulin, use a GLP-1 medication, take blood pressure medication, are pregnant or nursing, are managing kidney or liver disease, or have surgery scheduled

In most cases, nausea is mild to moderate in severity , and it gradually subsides with continued use of the medication